For example, triggering TLR responses (such as by administering a TLR9 agonist) in tumor cells can lead to the induction of tumor cells death 14, which, under certain conditions, is associated with antitumor immunity induction by mechanisms involving immunogenic or immunostimulatory cell death 15. This evidence concerns the gene TLR9 and neoplasm.